PND10 Predicting the long-term clinical effectiveness of daclizumab in relapsing-remitting multiple sclerosis: A new modeling framework using discrete event simulation  by Guo, S. et al.
 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  A101 
 
 
PND6  
CONNECTEDCARE FOR MS: IMPACT OF MANAGED THERAPY ON ADHERENCE 
TO MULTIPLE SCLEROSIS MEDICATIONS  
Staskon F1, Clark B2, DuChane J2, Miller R3, Love K1, Duncan I2 
1Walgreens Co, Deerfield, IL, USA, 2Walgreen Co., Deerfield, IL, USA, 3Walgreens Co, Carnegie, 
PA, USA  
BACKGROUND: A large national retail pharmacy chain developed a patient-
centric program providing enhanced levels of monitoring and care for patients 
taking MS Specialty Drugs as dispensed in a retail setting. MS biologics covered 
in the ConnectedCare for Multiple Sclerosis (CCMS) program during this analysis 
period included Avonex, Betaseron, Copaxone, Extavia, and Rebif. OBJECTIVES: 
To compare adherence rates for MS biologics between managed and non-
managed patients new to retail pharmacy or the CCMS program. The effect of 
health complications on adherence rates was also assessed. METHODS: This was 
a retrospective analysis of MS patients new to therapy (or pharmacy chain) 
during the initial six months of CCMS. Patients were followed for one year. 
Adherence was measured using proportion of days covered (PDC). For the 
primary objective, propensity scores based on patients’ gender, age, presence of 
chronic comorbidities, and pre-study adherence to chronic medications were 
used to match the CCMS intervention group to a comparisons group. Sub-group 
analysis on health complications (chronic medication comorbidity, or 
assessment screenings for depression and fatigue) used Analysis of Covariance 
to adjust for the propensity variables when examining PDC in the presence of 
health complications across managed cohorts. RESULTS: Mean PDC was nearly 
10% higher for the managed CCMS patients than for non-managed patients. 
Patients not managed with at least one chronic comorbidity had about an 11% 
lower PDC than non-managed patients without a comorbid condition, whereas, 
managed patients indicated little difference in relation to the presence of a 
comorbidity. Adherence levels were also reduced for non-managed patients 
reporting fatigue and depression, yet self-reports of fatigue and depression did 
not significantly affect adherence levels among managed patients. 
CONCLUSIONS: The provision of medication therapy management for MS 
patients significantly increases adherence to MS biologic medications. Among 
non-managed patients, adherence is even further reduced among patients with 
fatigue and depression.  
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OBJECTIVES: To assess the clinical and economic burden of Alzheimer’s disease 
in the U.S. veteran population. METHODS: Data from the Veterans Health 
Administration (VHA) Medical SAS Datasets was used to conduct a retrospective 
study (October 1, 2005 - May 31, 2012). Patients diagnosed with Alzheimer’s 
disease throughout the study period were identified using International 
Classification of Disease 9th Revision Clinical Modification (ICD-9-CM) diagnosis 
code 331.0. Health care resource utilization and costs were assessed in the 12-
month follow-up period, and clinical status was examined for the 12-month 
baseline period before disease identification. Major treatments during the 60 
days after disease identification were also studied. All descriptive statistical 
analyses were performed using SAS v9.3 software. RESULTS: A total of 54,161 
Alzheimer’s disease patients were identified in the VHA population during the 
study period. The most common comorbidities for Alzheimer’s disease patients 
were hypertension (n=14,387, 26.56%), followed by mental disorders (n=13,440, 
24.81%), diabetes (n=7,440, 13.74%) and memory loss (n=4,850, 8.95%). Other 
comorbidities included senile dementia and hearing loss. The top three 
treatments for Alzheimer’s disease were donepezil hydrochloride (n=16,526, 
30.51%), simvastatin (n=16,010, 29.56%), and memantine (n=11,081, 20.46%). 
Outpatient services were utilized by 98.62% of Alzheimer’s patients, followed by 
pharmacy (86.75%) and inpatient visits (30.29%). Outpatient ($7,650, [standard 
deviation] SD=$12,539), pharmacy ($1,660, SD=$2,688), and inpatient costs 
($16,790, SD=$75,963) contributed to follow-up health care expenditures. 
CONCLUSIONS: The U.S. veteran Alzheimer’s disease patient population had 
high percentages of comorbid conditions, including hypertension and mental 
disorders, as well as outpatient and inpatient visits. Further analysis is needed to 
evaluate the extent to which the treatment of Alzheimer’s disease is complicated 
by the presence of these comorbidities.  
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OBJECTIVES: To examine the comorbidities and economic burden of patients 
diagnosed with multiple sclerosis (MS) in the U.S. veteran population. METHODS: 
The study sample was extracted from the Veterans Health Administration (VHA) 
Medical SAS datasets from October 1, 2005 through May 31, 2012. All patients 
diagnosed with MS throughout the study period were identified using 
International Classification of Diseases 9th Revision Clinical Modification (ICD-9-
CM) diagnosis code 340.xx. Comorbid conditions were assessed for the 1-year 
baseline period before the MS identification date, and health care utilization and 
costs were assessed for 1 year of follow-up after the identification date. 
Statistical analyses were performed using SAS v9.3 software. RESULTS: There 
were 9,798 MS patients from 2005 to 2012 in the U.S. veteran population. The 
most frequent comorbidity for MS patients was hypertension (15.04%). All other 
comorbidities, including among others diabetes, depressive disorder, and 
lumbago, had frequencies of less than 10%. Common treatment medications for 
MS were simvastatin, omeprazole, lisinopril, and gabapentin. A total of 9,724 
(99.24%) MS patients had outpatient visits, while 8,471 (86.46%) patients had 
pharmacy visits and 1,976 (20.17%) inpatient visits. Outpatient, pharmacy and 
inpatient costs were $11,349 (standard deviation [SD]=$19,068), $3,220 
(SD=$7,285), and $9,171 (SD=$57,129), respectively. CONCLUSIONS: MS treatment 
is complicated by the presence of comorbidities. Further analysis in the context 
of complicated comorbid condition diagnoses is required to improve the overall 
burden of illness of MS patients.  
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OBJECTIVES: To validate a Chinese version of NUCOG METHODS: Accepted 
translation procedures were followed to develop a Chinese version of NUCOG. 
Patients from two hospitals were recruited between July and October, 2012. 
Statistical analysis was performed using SPSS 20.0. Subgroup analysis according 
to diagnosis was performed. Receiver Operating Characteristic (ROC) curves were 
utilized to test criterion validity. Convergent validity was assessed via 
correlations between NUCOG and MMSE and internal consistency was measured 
to test the reliability. RESULTS: 529 subjects comprised of patients with epilepsy 
(n=144), neurological diseases (n=81), dementia (n=44), control group (n=260) 
completed NUCOG and MMSE. Overall, both NUCOG and MMSE scores differed 
significantly across four groups with dementia<epilepsy=neurology<controls 
(p<0.0001). The subscale-by-group analysis of NUCOG indicated different 
cognitive patterns for four groups, with patient groups scoring lowest in memory 
and executive domains. All the four groups achieved higher scores in the 
language domain than in other domains. The NUCOG, but not the MMSE, 
discriminated between patients with simple partial and secondary 
generalized/tonic-clonic generalized seizures, stroke and Transient Ischemic 
Attack (TIA). Compared to the MMSE, the NUCOG exhibited higher area under 
the ROC curve (0.969 vs. 0.915) to detect dementia among patients. A premium 
cutoff score of 70.5 gave a sensitivity of 0.955 and specificity of 0.875 to detect 
dementia in the patient groups for NUCOG. The convergent validity was 
substantially correlated across entire sample, with Spearman’s r of 0.787 
(p<0.0001). Internal consistency of NUCOG by Cronbach’s α was 0.922. 
CONCLUSIONS: The Chinese version of NUCOG was demonstrated to be a 
sensitive, reliable screening tool for cognitive impairment. NUCOG could also 
better differentiate patients with certain seizure types, stroke and TIA compared 
to the MMSE. This would potentially expand the clinical usefulness of NUCOG in 
enabling clinicians to measure the cognitive profile of patients with epilepsy and 
ischemic cerebrovascular diseases.  
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OBJECTIVES: SELECT, a one-year phase II randomized controlled trial (RCT), 
showed benefits for daclizumab high-yield process 150mg (DAC HYP) versus 
placebo on relapses and disability among patients with relapsing-remitting 
multiple sclerosis (RRMS). This analysis utilized discrete-event simulation (DES) 
to model the potential long-term clinical implications of this trial. METHODS: An 
RRMS DES model that predicts the course of relapses, disability 
progression/regression, conversion to secondary-progressive MS (SPMS), and 
death was developed. During the RR phase, the occurrence of relapses could lead 
to change in patient’s Expanded Disability Status Scale (EDSS) scores, which in 
turn influences the risk of relapses. Both endpoints are predicted based on 
treatment and other predictors using two interrelated equations derived from 
four RCTs of RRMS patients (n=4,189), including SELECT, AFFIRM, CONFIRM, and 
DEFINE. Treatment can be stopped for various reasons and was assumed to have 
no residual effect at discontinuation. Conversion to SPMS or death could occur at 
any time and are predicted based on patient’s EDSS scores and other relevant 
characteristics using published epidemiological data. RESULTS: Over 20 years, 
patients on DAC HYP were predicted to result in: i) fewer relapses per patient (5.1 
vs. 7.2); ii) a higher proportion of patients free of any relapse (24% vs. 16%); iii) a 
lower percent of patients progressing to SPMS (69% vs. 74%), and iv) more time 
spent in less severe disability states (15.1 vs. 14.3 years in EDSS<7) compared to 
those without treatment. Life expectancy was also longer for patients on DAC 
HYP, but the difference was small. These outcomes were most sensitive to model 
time horizon. CONCLUSIONS: Long-term modeling based on the SELECT trial 
outcomes suggests that DAC HYP has a positive impact on key outcome 
measures of interest to patients with RRMS and their clinicians. Evidence from 
its phase III trial is still needed to support its use.  
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